Yi HanDulkeith Ph.D.

Of Counsel

Nova Iorque + 1.212.326.3845

Dr. Yi Han Dulkeith has global experience practicing across a wide spectrum of intellectual property matters. Her practice involves strategic portfolio management and prosecution, due diligence, opinion work, and post-grant proceedings. Yi's primary technical areas include biotechnology and pharmaceuticals, with advanced experience in immunotherapy, cell therapy, gene editing, stem cell technology, biomarkers, and diagnostics.

Yi focuses on strategic portfolio development and counseling clients in various patent-related areas including product clearance, licensing, acquisition due diligence, and IPO-related diligence. Yi has advised multinational biopharmaceutical companies on patent prosecution of novel antibody technologies and diagnostic and surrogate biomarkers for therapeutic antibodies and IP diligence for product clearance in connection with antibody manufacturing and medical devices; health care organizations and companies on patent prosecution of cell therapies and immunotherapies and counseling on licensing opportunities; start-up biotechnology companies on patent prosecution of gene editing technologies and cell therapies; and investment companies on evaluation of IP assets of target companies.

She also has handled patent prosecution matters and opinions and has directed and devised strategies in reexamination proceedings before the United States Patent and Trademark Office (USPTO).

While earning her doctorate and master's degrees at Yale, Yi pioneered an in-depth study on an alcohol metabolism gene and its protective role in preventing alcoholism. She has published her findings in peer-reviewed scientific journals and presented at national conferences. She has been recognized as a "rising star" by New York Super Lawyers numerous times.


  • Fred Hutchinson Cancer Research Center defeats IPR petition brought by Miltenyi Biomedicine GmbHJones Day represented patent owner Fred Hutchinson Cancer Research Center, on behalf of exclusive licensee Bristol Myers Squibb, in successfully defeating a patent challenge in an inter partes review (IPR) proceeding brought by petitioners Miltenyi Biomedicine GmbH and Miltenyi Biotec Inc. ("Miltenyi") in the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB).